Now the country’s total coronavirus case stands at 51,18,253.

COVID-19 Testing Update. For more details visit: https://t.co/dI1pqwfbRz @MoHFW_INDIA @DeptHealthRes #ICMRFIGHTSCOVID19 #IndiaFightsCOVID19 #CoronaUpdatesInIndia #COVID19 pic.twitter.com/joQaGm2E7R

— ICMR (@ICMRDELHI) September 17, 2020

According to Union health ministry update on Thursday morning, the number of active cases crossed the million mark and currently stand at 10,09,976 whereas 40,25,079 patients have been discharged from hospitals.

The recovery rate has further improved to 78.53 per cent, the health ministry said.
It further said that nearly 59 per cent of the new recoveries came from five states – 23.41 per cent from Maharashtra (19,423 recoveries); and a cumulative 35.5 per cent from Andhra Pradesh (9,628 recoveries), Karnataka (7,406), Uttar Pradesh (6,680) and Tamil Nadu (5,735).

Twenty-seven states and union territories are reporting recovery rates of more than 70 per cent, the ministry highlighted.

Meanwhile, Pune-based Serum Institute of India (SII) on Wednesday received the approval from the Drugs Controller General of India (DCGI) to resume clinical trials for the Covid-19 vaccine candidate developed by United Kingdom’s Oxford University and AstraZeneca.

The trials in India were paused last week after a trial subject in the United Kingdom developed an unexplained severe adverse reaction.

On September 16, the Supreme Court said that the central government has approved the use of Remdesivir and Fabiparivir as medicines to treat the coronavirus disease.

The top court was hearing a plea by the CBI against ten Indian pharmaceutical firms for manufacturing and selling these two medicines to treat the coronavirus disease.

Globally, nearly 30 million people have been infected with as many as 939,427 fatalities. The United States continued to the worst affected followed by India and Brazil. India, however, remained on top of the recoveries chart.

The post COVID-19: Over 97,000 cases in single day spike appeared first on The Gulf Indians.

Cipla is planning to supply over 80,000 vials within the first month. To ensure equitable distribution, the drug will be available through government and hospital channels.

Cipremi has been approved by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need.

Pharmaceutical major Mylan NV has also said that its generic version of remdesivir will be priced at Rs 4,800 per 100 mg vial.

Hyderabad-based drug firm Hetero has said it has fixed a maximum retail price of Rs 5,400 per vial for the drug.

Remdesivir is the only United States Food and Drug Administration (USFDA)-approved Emergency Use Authorisation (EUA) treatment for adult and pediatric patients hospitalised with suspected or laboratory-confirmed COVID-19 infection.

In May, domestic pharma firms Hetero, Cipla and Jubilant Life Sciences entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of remdesivir.

The launch of the Indian version of the generic drug came at a time when US government officials, on June 29, said that they bought more than 500,000 treatment courses of antiviral drug remdesivir, for next three months and effectively excluding other countries from accessing the drug.

The post Cipla launches generic version of remdesivir in India appeared first on The Gulf Indians.